What is ProSolus?
ProSolus Pharmaceuticals is a specialized pharmaceutical company dedicated to the research, development, and global manufacturing of transdermal and topical patch technologies. Their innovative product range addresses critical therapeutic areas, including pain management, cardiovascular conditions, and neurological disorders. Operating from a state-of-the-art facility in Miami, Florida, ProSolus is committed to providing bespoke solutions for its clientele, leveraging advanced drug delivery systems from formulation through to final packaging. The company actively collaborates with suppliers to refine and enhance its product offerings, ensuring a sophisticated and effective patient experience.
How much funding has ProSolus raised?
ProSolus has raised a total of $637K across 2 funding rounds:
Debt
$350K
Debt
$287K
Debt (2020): $350K with participation from PPP
Debt (2021): $287K led by PPP
Key Investors in ProSolus
PPP
Public-Private Partnership
PPP
Public-Private Partnership
What's next for ProSolus?
The substantial enterprise-level capital infusion positions ProSolus Pharmaceuticals for accelerated growth and enhanced research and development initiatives. This strategic backing is expected to fuel the expansion of their manufacturing capabilities and the advancement of their pipeline of transdermal and topical patch solutions. Future endeavors will likely focus on broadening their market reach, forging new strategic partnerships, and potentially exploring new therapeutic categories. The company's commitment to innovation in drug delivery systems suggests a forward-looking strategy aimed at solidifying its market leadership and delivering advanced healthcare solutions globally.
See full ProSolus company page
